Helmholtz Munich

What Helmholtz Munich does

Helmholtz Munich (legal entity: Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH) is a publicly funded German research center and one of 19 institutes in the Helmholtz Association, headquartered in Neuherberg near Munich. Founded in 1960 with 1,001–5,000 employees, the center pursues mechanistic and translational research on environmental health, metabolic disease (diabetes, obesity), cancer, and neurological disorders, operating through six thematic research centers: Diabetes (HDC), Environmental Health (EHC), Molecular Targets and Therapeutics (MTC), Stem Cell, Bioengineering, and Computational Health. Its work spans population cohorts (the 40-year KORA study in Augsburg), single-cell biology (leading the Human Lung Cell Atlas with 2.4 million cells), and clinical imaging modalities (MSOT, RSOM, fast-RSOM, MiROM).

The center's technology stack is anchored in AI and machine learning applied to biomedical imaging, single-cell genomics, and foundation models for health. Proprietary assets include DeepMB (1000x faster optoacoustic reconstruction), MouseMapper (whole-body cellular alteration mapping), RegVelo (gene-regulatory-network + RNA-velocity framework), scPoli (generative single-cell integration), and a portfolio of foundation models for disease pattern recognition. Imaging innovations such as MSOT have been commercialized through the spin-off iThera Medical GmbH, and an experimental GLP-1/GIP/PPAR quintuple agonist is under development for metabolic disease.

The business model is non-commercial: Helmholtz Munich is funded primarily through the German Federal Ministry of Education and Research (BMBF) and state governments as part of the Helmholtz Association, supplemented by competitive grants (ERC, Horizon Europe, DFG) and third-party project funding. There is no disclosed commercial revenue, no pricing model for products, and no traditional go-to-market motion. Instead, the center monetizes impact through peer-reviewed publications, open-access datasets, technology transfer to industry partners, spin-off formation (e.g., iThera Medical), and collaborative research agreements with universities (TUM, Oxford, Tsinghua, UMass Amherst), consortia (Human Cell Atlas, PUREPOLIS), and industry stakeholders.

Name

Helmholtz Munich

Legal name

Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

Website

https://helmholtz-munich.de

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Helmholtz Munich is a publicly funded German biomedical research center within the Helmholtz Association, applying AI, single-cell genomics, optoacoustic imaging, and metabolic disease research to translate discoveries into prevention, diagnostics, and therapeutics for global health challenges.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), One Health & Zoonotic Disease Partnerships (Human–Animal–Environment) (HLAJAOAJ)

Keywords

• Biomedical research
• Computational biology
• Medical imaging technology
• Translational medicine
• Environmental health research

Headquarters

HQ city

Neuherberg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Distribution channels3 records

Marketing channels4 records

Core offering

Helmholtz Munich is a publicly funded German biomedical research center that conducts fundamental and translational research on environmental health, metabolic diseases (diabetes and obesity), cancer, and neurological disorders. It delivers research outputs including AI foundation models, deep-learning frameworks, optoacoustic imaging technologies, single-cell atlases, and therapeutic candidates, and transfers these to industry via spin-offs and collaborative agreements.

Product overview

Helmholtz Munich is a strategic biomedical research center operating as a multi-disciplinary platform with specialized research centers focused on diabetes and obesity, environmental health, molecular therapeutics, stem cells, bioengineering, and computational health. The portfolio includes AI foundation models for health research, advanced imaging technologies (DeepMB, RSOM, MSOT, fast-RSOM, MiROM), AI-powered analytical frameworks (MouseMapper, RegVelo, scPoli), and comprehensive cell atlases (Human Lung Cell Atlas). The Computational Health Center coordinates Helmholtz AI, a national AI platform. Research centers collaborate through programs like the Helmholtz Biomedical Engineering Initiative, while the Helmholtz Pioneer Campus serves as an innovation hub for biomedical engineering.

Differentiator

Problem solved

Functional benefit

Brands

• Helmholtz Diabetes Center (HDC): Research center focused on diabetes and metabolic diseases, comprising multiple institutes including Adipocytes and Metabolism, Diabetes and Cancer, Diabetes and Endocrinology, Experimental Genetics, and others.
• Environmental Health Center (EHC)
• Computational Health Center
• Stem Cell Center
• Bioengineering Center
• Molecular Targets and Therapeutics Center (MTC)
• Helmholtz Pioneer Campus
• Helmholtz AI
• PUREPOLIS
• Human Lung Cell Atlas

Products and services

• DeepMB A deep-learning framework that reconstructs high-resolution optoacoustic images in real time, approximately 1000x faster than previous methods without compromising image quality; intended for clinical imaging applications.
• MouseMapper (AI Atlas) AI framework using deep learning, fluorescent markers, and light-sheet microscopy to map disease-induced cellular alterations across the entire mouse body at cellular resolution; used for studying diabetes, cancer, neurodegeneration, and autoimmune disorders.
• RegVelo AI-driven computational framework that integrates gene regulatory networks with single-cell RNA velocity to model and predict cellular fate decisions for biomedical researchers.
• fast-RSOM Non-invasive optoacoustic mesoscopy technology that detects early signs of cardiovascular disease by capturing high-resolution images of the smallest blood vessels through the skin at single-capillary resolution.
• MiROM Mid-infrared optoacoustic microscopy enabling label-free visualization of molecular presence in cells and tissues without dyes or markers, for single-cell-level assessment of cancer treatment responses.
• Human Lung Cell Atlas (discovAIR) First holistic single-cell atlas of the human lung integrating 49 datasets from over 100 healthy individuals; serves as a comprehensive reference for understanding lung biology in health and disease.
• scPoli Generative AI model for data integration of high-resolution single-cell datasets, used by researchers to analyze large-scale medical datasets.
• MSOT (Multispectral Optoacoustic Tomography) Scanner Multispectral Optoacoustic Tomography scanner developed by Prof. Vasilis Ntziachristos, utilizing the optoacoustic effect to produce detailed medical images for clinical assessment; commercialized via the iThera Medical GmbH spin-off.
• RSOM (Raster-Scan Optoacoustic Mesoscopy) Raster-Scan Optoacoustic Mesoscopy technology enabling detailed visualization of biological structures within and below the skin, supporting understanding of complex disease processes.

Quantifiable outcome

• MouseMapper identified 31 organ and tissue types with widespread changes in obese mice
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Eleven partnerships are on record, tiered major, core and moderate.

• Vector InstitutemajorStrategic or Co-development Partner · 11 June 2026MOU signed between Vector Institute and Helmholtz Munich's Computational Health Center to strengthen international collaboration in AI and machine learning research. Establishes formal framework for joint research, researcher exchanges, faculty affiliations, and coordinated engagement in bilateral funding programs spanning Canada and Germany.
• iThera Medical GmbHcoreTechnology or IntegrationSpin-off company commercializing MSOT (Multispectral Optoacoustic Tomography) technology developed by Prof. Vasilis Ntziachristos at Helmholtz Munich and TUM. The company markets and further develops the technology for clinical applications.
• Technical University of Munich (TUM)coreStrategic or Co-development PartnerLong-standing collaboration on multiple research projects including Human Lung Cell Atlas, MSOT development, computational biology, and bioengineering research. TUM is a key academic partner with shared faculty appointments.
• University Hospital AugsburgmajorStrategic or Co-development PartnerCollaborative research on environmental health including nighttime heat and stroke risk studies, analyzing 15 years of stroke data from the hospital's neurology department.
• Stowers Institute for Medical ResearchmajorStrategic or Co-development PartnerCollaboration on RegVelo AI framework development for predicting cellular fate decisions using zebrafish neural crest as model system.
• University of OxfordmajorStrategic or Co-development PartnerAcademic partner in RegVelo AI framework development alongside Stowers Institute and TUM.
• Human Cell Atlas ConsortiumcoreStrategic or Co-development PartnerInternational consortium with goal of creating reference maps of all human cells. Helmholtz Munich leads the Human Lung Cell Atlas as founding member.
• University of Massachusetts AmherstmajorStrategic or Co-development PartnerLed international study identifying 676 genes causally linked to Type 2 diabetes risk across 7 diabetes-relevant tissues using genetic data from 2.5 million people worldwide.
• Tsinghua UniversitymajorStrategic or Co-development PartnerCollaboration on exercise endurance research showing B cells' non-immune role in supporting muscles during exercise.
• PUREPOLIS ConsortiummajorStrategic or Co-development Partner€4.9 million Horizon Europe project coordinated by Helmholtz Munich with 19 consortium partners from research, technology, public authorities, and civil society. Core cities: Nantes, Valencia; Follower cities: Berlin, Rybnik, Augsburg.
• Canada-Germany Digital AlliancemoderateGTM or Marketing PartnerBilateral funding program facilitating AI and ML research collaboration between Canada and Germany under the Vector Institute-Helmholtz Munich MOU.

Scale indicators11 records

Recent moves10 records

Expansion highlights5 records

Market position

Strengths5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/helmholtzmunich
• YouTubeyoutube.com/user/helmholtzmuenchen
• LinkedInde.linkedin.com/company/helmholtz-munich
• Instagraminstagram.com/helmholtz_munich
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helmholtz Munich